in size and visible on T2-weighted MRI for inclusion in our analysis; those visible only on susceptibility-weighted imaging were excluded.
data collection and analysis
We reviewed patient charts to determine the following information: age at presentation, sex, modality of presentation, CM location, CM multiplicity, CM family history, history of radiation, and associated developmental venous anomaly (DVA). The time of initial clinical and radiological (MRI) diagnosis was noted, as was the time of the last clinical and radiological follow-up. The development of any new T2-visible CMs at least 4 mm in size at the radiological follow-up was also recorded.
To be included in our analysis of annual hemorrhage risk, patients had to have at least 1 month of untreated follow-up; this included patients ultimately undergoing resection of their CM. Follow-up was tallied in lesion-years from the time of initial presentation until the last clinical follow-up or initiation of treatment. Hemorrhage was defined as the presence of new acute bleeding on imaging, with an associated new neurological deficit, seizure, and/ or apoplectic presentation. Annual hemorrhage rates were calculated as the ratio of the number of bleeds to the total number of lesion-years of follow-up.
statistical analysis
For our analysis of hemorrhage risk, the primary outcome measure was symptomatic hemorrhage. Time 0 was defined as age at presentation, and the first hemorrhage after presentation was used as the censoring event (right censoring). To explain the variability in the primary outcome, we examined 7 variables per lesion: age, sex, presentation modality (seizure, hemorrhage), location (brainstem vs nonbrainstem), CM family history, CM multiplicity, and associated DVAs. The Survival package in R, version 2.14, was then used to calculate hazard ratios using the univariate and multivariate Cox proportional hazards regression models. A p value < 0.05 was considered significant.
results background and demographics
In this cohort of 167 patients with 222 CMs, the mean patient age at the time of diagnosis was 10.1 years (SD 6.0, range 0.1-21 years; Table 1 ). Ninety patients (54%) were male. One hundred four patients (62%) presented with hemorrhage from at least 1 CM, 58 (35%) with seizures with or without CM hemorrhage, and 43 (26%) with incidental lesions. Twenty-five patients (15%) had multiple CMs, 17 (10%) had a family history of CMs, and 33 (20%) had radiologically apparent DVAs. One hundred seventyfour CMs were supratentorial lobar (78%), 18 (8%) were in the brainstem, 16 (7%) were in the basal ganglia or thalamus, and 14 (6%) were in the cerebellum. Interestingly, half (7 of 14) of the cerebellar CMs were associated with DVAs as compared with 21% of the brainstem CMs, 19% of the supratentorial deep CMs, and 15% of the supratentorial lobar CMs (p = 0.01 for comparison of cerebellar CMs to all other locations by Fisher exact test).
de novo cM development
Over a total of 789.5 patient-years of radiological (MRI) follow-up from the time of an initial radiological diagnosis of at least 1 CM, 20 de novo CMs, each measuring at least 4 mm on T2-weighted MRI, were noted in 10 patients. This corresponds to an annual incidence of 2.5% per lesion or 1.2% per patient ( Table 2) . Six of these patients had initially presented with multiple CMs (60%; 3 had a known family history of CMs), and 2 had undergone prior radiation (20%). Two patients had presented with solitary lesions: 1 was an infant with von Willebrand's disease who subsequently developed 2 de novo frontal lesions at the age of 4 years.
Twenty-five patients initially presenting with multiple CMs had 198.5 patient-years of radiological follow-up. Six of these patients developed 14 de novo CMs (measuring at least 4 mm on T2-weighted MRI), corresponding to an annual rate of 7.1% per lesion or 3.0% per patient (Table 2) . Fifteen patients with radiation-induced CMs had 117 patient-years of radiological follow-up from the time of initial radiological diagnosis of their CMs. Two of these patients developed 3 de novo CMs at least 4 mm on T2-weighted imaging, corresponding to an annual rate of 2.6% per lesion or 1.7% per patient. Across the remaining group of patients presenting with single nonfamilial CMs without a prior history of radiation, the annual rate of de novo CM development was 0.6% per lesion or 0.4% per patient. (7) 14 (6) 18 (8) 
radiation-induced cMs
Fifteen patients (9%) had 23 CMs that developed after prior radiation. Eight of these patients (53%) were treated for acute lymphocytic leukemia, 4 (27%) for medulloblastoma, and 1 each (7%) for ependymoma, germinoma, and neuroblastoma. Mean patient age at the time of radiation was 5.2 years old (SD 2.3), and the mean latency until radiological diagnosis of the CM was 9.3 years (SD 4.8).
There was no significant sex predilection in this cohort (8 males [53%]). Seven patients (46%) presented with hemorrhage and 4 (27%) with seizures with or without hemorrhage. Seven patients (46%) were initially asymptomatic despite their lesions. Cavernous malformation location was predominantly supratentorial lobar (21 [91%] of 23); 1 lesion (4%) was in the cerebellum and another (4%) was in the basal ganglia. None of these CMs were associated with a DVA.
hemorrhage rate and Morbidity
One hundred fifty-nine patients with 193 CCMs had at least 1 month of untreated follow-up and were included in our analysis of annual hemorrhage rate (follow-up range 0.1-16.4 years, mean 3.8 years). Over a total of 726.3 lesion-years, 24 hemorrhages occurred, corresponding to an overall annual hemorrhage rate of 3.3% per lesion-year (Table 3) . For 73 incidental CMs, the annual hemorrhage rate was 0.5%. Notably, 63 (86%) of these incidental CMs had at least 1 year of untreated follow-up, and 36 (49%) had at least 5 years of untreated follow-up. The annual hemorrhage rates in these 2 subgroups remained consistent at 0.5% and 0.3%, respectively. For 43 patients presenting with solitary incidental CMs, the annual hemorrhage rate was 1.2%.
The annual hemorrhage rate for hemorrhagic CMs was 11.3%, increasing to 18.2% within the first 3 years of a CM hemorrhage. This rate decreased to 4.8% after 3 years and to 3.3% after 5 years; however, only 11 hemorrhagic CMs had 5 years of untreated follow-up in this analysis. We noted trends for higher hemorrhage rates among CMs that were nonmultiple and those associated with DVAs. Brainstem CMs had a notably greater annual hemorrhage rate (16.7% per lesion-year) than CMs in any other location, although the majority of these were initially hemorrhagic at presentation (14 [82%] of 17). Permanent neurological morbidity, defined as a lasting neurological deficit at the last follow-up, was 29% per hemorrhage, increasing to 45% for brainstem, thalamic, or basal ganglia CM and decreasing to 15% for supratentorial lobar or cerebellar lesions. No mortality was associated with any CM hemorrhage in this series.
hemorrhage risk Factors
A summary of univariate and multivariate analyses of risk factors for hemorrhage is provided in Table 4 (Fig. 1) . In a post hoc univariate analysis, hemorrhage clustering within 3 years was statistically significant (HR 6.1, 95% CI 1.72-21.7, p = 0.005) as compared with the hemorrhage rate after this initial period.
discussion
Cerebral CMs are angiographically occult vascular malformations comprised of a collection of dilated sinusoidal vessels lined by a flattened endothelium without a reinforcing elastin or smooth muscle layer or a surrounding thin fibrous adventitia. 7, 8, 22, 23 The sinusoids contain blood of various ages and are directly apposed without intervening neural parenchyma in contradistinction to cerebral capillary telangiectasias. 7, 8, 10, 22 Their natural course in the pediatric population remains relatively obscure, with only one recent study systematically evaluating their prevalence and natural course in children. 2 The current analysis features the largest reported pediatric cohort with CMs. We excluded lesions smaller than 4 mm as a means of improving our study's reproducibility and external validity and reducing interobserver variability; however, this may exclude a cohort of relatively quiescent lesions and thus inflate our study's conclusions of lesion aggressiveness (seizure risk, hemorrhage risk). On the other hand, asymptomatic or mildly symptomatic events may have been missed. Consistent with data in the adult literature, an overall imaging prevalence of 0.6% for CMs in children was reported in a recent study; 2 however, the rate was lowest among infants (0.2%) and increased with advancing age. In our study, we found no significant sex predilec- tion among pediatric patients with CMs, consistent with a prior pediatric study 2 as well as with a collective analysis of studies in adults. 10 Although potentially influenced by referral patterns, our 10% rate of familial CM cases, as well as the 15% rate of patients with multiple CMs, was also consistent with a prior collective analysis of CMs in adults. 10 Our analysis demonstrated that cerebellar CMs had greater proclivity for an association with radiologically apparent DVAs, a finding not previously reported. Although venous abnormalities have been implicated in the genesis of CMs, 1,5,10 most studies, like our own, have demonstrated that radiologically apparent DVAs are seen in association with CMs in only 10%-20% of cases. 10, 14, 20 Though authors of early studies hypothesized increased lesion aggressiveness for CMs associated with DVAs, 21 the presence of such lesions is infrequently evaluated as a risk factor for hemorrhage in natural history studies in adults. 10, 12, 14, 20 However, in the one other study evaluating the natural course of CMs in pediatric patients, a notable trend toward a greater hemorrhage rate for CMs associated with DVAs was reported with a p value of 0.06.
2 This finding was consistent with data in our study, potentially as a result of added statistical power, which revealed DVAs as a statistically significant risk factor for hemorrhage (HR 2.91, 95% CI 1.04-8.09, p = 0.04).
Although we found the annual rate of de novo CM development to be 2.5% per lesion and 1.2% per patient, this rate was influenced by CM multiplicity and prior radiation. Patients with solitary CMs developed de novo lesions at a rate of 0.6% per lesion; this rate increased to 7.1% for patients with multiple CMs and to 2.6% for those with prior radiation.
Radiation-induced CM development was seen in 9% of patients in this study, and notably none of these patients had radiologically apparent DVAs. Cavernous malformation development can occur after either conventional radiation 16 or stereotactic radiosurgery, 15, 17 though all patients with radiation-induced cerebral CMs in this study had undergone conventional fractionated radiation. A prior systematic review of 76 patients with radiation-induced CMs showed a mean patient age of 11.7 years with a latency of 8.9 years after radiation until CM detection, 16 quite consistent with results seen in our study. Precluding a meaningful analysis of the natural history of radiation-induced CMs, all but 1 hemorrhagic, radiation-induced CM in our cohort was treated with early surgery.
hemorrhagic cMs
Potentially influenced by referral bias, 62% of patients in this report presented with hemorrhagic CMs. As shown in this study and in several prior analyses, hemorrhage is a statistically significant risk factor for subsequent hemorrhage. 3, 6, 7, 9, 10, 12 In addition, our analysis was consistent with multiple prior adult and 1 prior pediatric study in demonstrating a 0.5% per lesion-year rate of hemorrhage for incidental CMs.
2, 3, 9, 10, 12 We found the overall annual hemorrhage rate for hemorrhagic CMs to be 11.3%; however, this rate was influenced by time from the initial hemorrhage, with statistically significant hemorrhage clustering occurring within 3 years of presentation. In a prior study by Barker et al., hemorrhage clustering was demonstrated within 2 years of presentation. 6 This finding is an important one for both patient counseling and evaluating the efficacy of stereotactic radiosurgery for cerebral CMs. Most studies on the latter have shown a statistically significant decrease in the CM hemorrhage rate after 2 years; 4, 11, 18, 19 it is unclear whether this rate, in fact, reflects the effect of radiosurgery or simply the natural history of the lesion. Given our findings, we recommend interval scanning at 3-6 months for hemorrhagic CMs deemed unsuitable for surgery; thereafter, these lesions can be followed annually. On the other hand, given the consistently low annual hemorrhage rate for incidental CMs in this study, including a 0.3% rate for a cohort with at least 5 years of follow-up, these lesions can be followed less frequently.
brainstem cMs
Located in highly eloquent brain parenchyma, brainstem CMs have consistently demonstrated more aggressive, clinically apparent natural courses in both pediatric and adult studies. 2, 10, 13, 20 In our analysis, 82% of brainstem CMs presented with hemorrhage along with a subsequent annual hemorrhage rate of 16.7%. While it is difficult to determine whether the high subsequent hemorrhage rate relates to the brainstem location or to the initial hemorrhagic presentation, this rehemorrhage rate is higher than that for hemorrhagic lesions presenting outside the brainstem. Another study dedicated to pediatric brainstem CMs reported a 79% rate of hemorrhagic presentation with a subsequent 11.7% annual hemorrhage rate. 13 Interestingly, 38.8% of conservatively managed pediatric patients with brainstem CMs were clinically improved at follow-up, while 37.6% were unchanged and 23.5% were worse. In fact, 25% of patients attained complete recovery, a rate that increased to 49.2% for those with at least 5 years of follow-up. It is important to underscore that both our study and this subgroup analysis of pediatric brainstem CMs clearly illustrate early hemorrhage clustering for this subgroup of CMs in particular.
conclusions
A prior hemorrhage, a brainstem location, and an associated DVA are significant risk factors for hemorrhage in children with CMs. Hemorrhage clustering within the first 3 years of a bleed can occur, a factor to consider in patient counseling and when reviewing results of studies on CM radiosurgery. 
